Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial-Reference-Cited by-同舟云学术

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

Published:2020-12 Issue:12 Volume:5 Page:1063-1075
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Atreya Raja,Peyrin-Biroulet Laurent,Klymenko Andrii,Augustyn Monica,Bakulin Igor,Slankamenac Dusan,Miheller Pal,Gasbarrini Antonio,Hébuterne Xavier,Arnesson Karin,Knittel Thomas,Kowalski Jan,Neurath Markus F,Sandborn William J,Reinisch Walter

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference32 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management;Harbord;J Crohns Colitis,2017

3. Ustekinumab as induction and maintenance therapy for ulcerative colitis;Sands;N Engl J Med,2019

4. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis;Ford;Am J Gastroenterol,2011

5. Ulcerative colitis: shifting sands;D'Haens;Drugs R D,2019

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FORWARD: A Learning Framework for Logical Network Perturbations to Prioritize Targets for Drug Development;2024-07-19

2. Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade;Frontiers in Immunology;2024-07-16

3. Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease;Immunopharmacology and Immunotoxicology;2024-07-03

4. Strategies for targeting cytokines in inflammatory bowel disease;Nature Reviews Immunology;2024-03-14

5. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials;Expert Review of Gastroenterology & Hepatology;2024-03-03